Steve Walsh
Principal Scientist - Project Leader Bicycle Therapeutics plc
Seminars
Wednesday 5th November 2025
Investigating the Performance of Zelenectide Pevedotin & BT5528 to Understand Class Effect Differences of Bicycle Drug Conjugates Against Traditional ADCs
11:00 am
- Laying out preclinical and emerging clinical profiles of zelenectide pevedotin and BT5528
- Making comparisons of the safety profiles of these BDCs versus traditional ADCs
- Exploring opportunities for Bicycle® molecules beyond drug conjugates
